Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Neurocrine Biosciences (NBIX) announced an analysis identifying a 6-point increase as clinically meaningful improvement in overall health for INGREZZA-treated tardive dyskinesia patients. The benchmark applies to the EQ Visual Analogue Scale, a patient-rated health measure ranging from 0 to 100, with higher scores indicating better health.
The threshold provides context for previously reported Phase 4 KINECT-PRO results: mean health scores improved 13.1 points from baseline at Week 24. Patient-reported tardive dyskinesia impact and clinician-rated movement severity exceeded their meaningful-change thresholds as early as Week 8 and Week 4, respectively, with improvements sustained through Week 24. KINECT-PRO was an open-label study. The new analysis is among three company analyses scheduled for presentation at the Academy of Managed Care Pharmacy Nexus conference, October 26–29, 2026.
Neurocrine Biosciences (NBIX) announced publication of expert perspectives on hyperphagia in Prader-Willi syndrome in Orphanet Journal of Rare Diseases.
The experts describe hyperphagia—persistent hunger and an intense drive to eat—as involving biological, behavioral, and environmental factors beyond food intake. They recommend assessment that considers food-related thoughts, caregiver perspectives, and environmental context, noting that structured environments can mask symptom severity. They also emphasize coordinated care across the lifespan, particularly during the transition to adulthood, and describe medication, including VYKAT XR, as a complement to behavioral and environmental support.
Neurocrine Biosciences (NBIX) has initiated a Phase 2 study of NBI-'567 in adults with mild to moderate Alzheimer's disease. The investigational oral drug is being evaluated as an add-on treatment for cognitive impairment in patients receiving stable treatment with an acetylcholinesterase inhibitor.
The randomized, double-blind, placebo-controlled study plans to enroll approximately 135 adults ages 50 to 85. It will compare once-daily high or low doses with placebo over 12 weeks, assessing efficacy, safety, tolerability and how the body processes the drug. The primary efficacy measure is change from baseline in a Neuropsychological Test Battery composite score at Week 12.
Neurocrine Biosciences (NBIX) announced real-world findings mapping how classic congenital adrenal hyperplasia affects patients across different stages of life. The analysis used records from 10 adults in the CAHtalog registry, covering more than 2,800 disease-relevant events and more than 300 patient-years of medical history.
Records showed childhood growth concerns, adolescent treatment challenges, reproductive and care-transition needs in young adulthood, and broader health concerns in adulthood. Treatment demands persisted, alongside effects on school, work and daily activities. The findings are qualitative and illustrative, not prevalence estimates or evidence of causality; some observations involved only one or two individuals.
Neurocrine Biosciences (NBIX) scheduled its third-quarter 2026 financial results conference call and webcast for November 2, 2026. The results release is scheduled for 1:00 p.m. Pacific / 4:00 p.m. Eastern, followed by the call at 1:30 p.m. Pacific / 4:30 p.m. Eastern. The webcast will be accessible through the company's investor website, with a replay available approximately one hour after the event and archived for approximately one month.
Neurocrine Biosciences (NBIX) will present Prader-Willi syndrome research at the FPWR Annual Research Symposium & Family Conference, October 7–10 in Philadelphia.
Presentations include baseline patient characteristics from PWS-VISTA, an ongoing observational study designed to track VYKAT XR use, long-term safety and treatment outcomes in routine practice. BRAVE-PWS will present the design of an ongoing study collecting caregiver-reported experiences. An integrated analysis will examine the timing and occurrence of fluid retention, high blood sugar and excess hair growth during treatment. Other presentations address long-term hyperphagia, or persistent excessive hunger, and resuming treatment after randomized withdrawal.
Neurocrine Biosciences (NBIX) named Eiry W. Roberts chief medical officer, effective immediately, and said Sanjay Keswani will depart by mutual agreement.
Roberts held the role from 2018 to 2025 and currently serves as a strategic advisor. During her earlier tenure, she led indication-expansion efforts for INGREZZA and the crinecerfont development program that led to U.S. Food and Drug Administration approval of CRENESSITY. Neurocrine said it is advancing multiple late-stage programs and preparing for several clinical milestones.
Neurocrine Biosciences (NBIX)/b) will participate in three investor conferences in September 2026, featuring executive fireside chats at Wells Fargo, Cantor and Morgan Stanley healthcare events.The sessions take place on September 9 in Boston, and September 10 and 15 in New York, with live and replay webcasts available via the company’s investor website.
Neurocrine Biosciences (NASDAQ: NBIX) reported publication of Phase 4 KINECT-PRO™ data showing once-daily INGREZZA (valbenazine) improved patient-reported quality of life and functioning in adults with tardive dyskinesia over 24 weeks. The open-label study (n=59; 45 in efficacy analyses) used multiple validated patient-reported outcomes, including the Tardive Dyskinesia Impact Scale (TDIS™), EQ-VAS and Sheehan Disability Scale, plus clinician-rated AIMS.
Mean improvements in TD impact (TDIS) and movement severity (AIMS) exceeded minimal clinically important difference thresholds and were sustained to Week 24 across psychiatric diagnoses and baseline severities. About 58% of patients met a clinician-defined symptomatic remission threshold at Week 24, and safety and tolerability were reported as consistent with the known INGREZZA profile, with no new concerns identified.
Neurocrine Biosciences (Nasdaq: NBIX) announced the initiation of a Phase 1 first-in-human clinical study of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. The trial will initially assess safety and tolerability of single ascending doses in adults across overweight and obese body mass index categories.
NBIP-'1968 is an internally discovered, long-acting candidate designed for once-weekly subcutaneous administration, with balanced glucagon receptor activity to support tolerability while targeting appetite regulation, energy balance and glycemic control. It is intended for fixed-dose combination use with NBIP-'2118, a corticotropin-releasing factor type 2 receptor agonist also in Phase 1 development, within Neurocrine’s broader obesity portfolio.